((2R,3S,4S,5R)-3-Acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-yl)methyl acetate

Catalog No. :
ACZFNK534
CAS No. :
25383-79-3
Molecular Formula :
C13H16N2O8
Molecular Weight :
328.28

IUPAC Name:((2R,3S,4S,5R)-3-acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-yl)methyl acetate

((2R,3S,4S,5R)-3-Acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-yl)methyl acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name((2R,3S,4S,5R)-3-Acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-yl)methyl acetate
IUPAC Name((2R,3S,4S,5R)-3-acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxytetrahydrofuran-2-yl)methyl acetate
Molecular FormulaC13H16N2O8
Molecular Weight328.28
SMILESO[C@@H]1[C@@](O[C@H](COC(C)=O)[C@H]1OC(C)=O)(N2C(=O)NC(=O)C=C2)[H]
InChI KeyPICUADGBUPLIHQ-SASUGWTJSA-N
Synonym1-(3-O,5-O-Diacetyl-β-D-arabinofuranosyl)uracil;2,4(1H,3H)-Pyrimidinedione, 1-(3,5-di-O-acetyl-β-D-arabinofuranosyl)-
CAS No.25383-79-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACZFNK534 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZFNK534 route product structure diagram
    ACZFNK53425383-79-3
Inquiry

2. ACZFNK534 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZFNK534 route product structure diagram
    ACZFNK53425383-79-3
Inquiry

Comments (0)